About Us

Company

FibroStatin SL was incorporated in 2005. The Company’s headquarters is located in the Scientific Park of the University of Valencia (Spain). The Company’s facility includes 300 m2 of laboratory space and administrative offices. The core activities including protein chemistry, molecular and cell biology, organic chemistry, histopathology and mass spectrometry, are performed on site by FibroStatin staff, whereas noncore activities such as pre-clinical, NMR, radioisotope, confocal and electron microscopy, and surface plasmon resonance, are subcontracted to outside laboratories. FibroStatin SLhas recently established a fully-own subsidiary in the USA, FibroStatin INC, which will conduct financing, business development, regulatory and clinical development activities. FibroStatin plans to advance its treatment candidate through clinical trials in collaboration with corporate partners.

Management Team

Juan Saus,
M.D., Ph.D.
Founder and Scientific Director of FibroStatin SL.
Juan Saus,
M.D., Ph.D.
Founder and Scientific Director of FibroStatin SL.
Associate Professor University of Valencia; Post-doc at the Robert Wood Johnson Medical School; Post-doc at Kansas University Medical Center. Dr. Saus has 37 peer-reviewed publications in referenced international journals, 3 book chapters, 10 international utility patent applications (PCT), and 29 issued patents.
Francisco Revert,
Ph.D.
Founder and Head of Molecular Biology and Biochemistry of FibroStatin SL.
Francisco Revert,
Ph.D.
Founder and Head of Molecular Biology and Biochemistry of FibroStatin SL.
Biological Sciences degree and Pharmacy PhD at University of Valencia; Post-Doc at Príncipe Felipe Research Center. Dr. Revert-Ros has over 18 years of experience in molecular basis of human disease, 9 peer-reviewed publications in referenced international journals, 5 international utility patent applications (PCT) and 5 Granted patents.
Fernando Revert,
Ph.D.
Founder and Head of Cell Biology and Member of FibroStatin SL BOD.
Fernando Revert,
Ph.D.
Founder and Head of Cell Biology and Member of FibroStatin SL BOD.
Pharmacy PhD at University of Valencia; Post-Doc at Principe Felipe Research Center. Dr. Revert-Ros has over 23 years of experience in molecular basis of human disease, 14 peer-reviewed publications in referenced international journals, 2 book chapters, 5 international utility patent applications (PCT) and 4 Granted patents.
Luis Castillo,
B.S.
General Manager and Member of FibroStatin SL BOD
Luis Castillo,
B.S.
General Manager and Member of FibroStatin SL BOD
Industrial Engineer and Engineering Advanced Studies degree at the Polytechnic University of Valencia. Experience 15+ years in R&D management. Project Manager at IBV and ITENE, Co-Founder of Spin-Off Manager SL, Head of Department at GVA-Spain government, General Manager at Celartia LTD.
J. Wesley Fox III,
Ph.D.
President and Chief Executive Officer of FibroStatin Inc and Member of the FibroStatin SL BOD.
J. Wesley Fox III,
Ph.D.
President and Chief Executive Officer of FibroStatin Inc and Member of the FibroStatin SL BOD.
Experience 25+ years. FibroStatin SL BOD; Co-Founder of NephroGenex, BioStratum, EnzyMed (acquired by Albany Molecular Research) and RiboGene (acquired by Questcore Pharmaceuticals). R&D positions with Abbott Laboratories and Baxter Healthcare.
J. Wesley Fox IV
J.D., RAC
Director of Business Development and Regulatory Affairs
J. Wesley Fox IV
J.D., RAC
Director of Business Development and Regulatory Affairs
RAC certified regulatory affairs consultant working with developmental stage pharmaceutical companies. FDA accelerated approval; Special Protocol Assessment (SPA); FDA?s Citizen Petition policy; FDA regulation of dietary supplements.

Scientific Advisory Board

Billy G Hudson,
Ph.D.
Director, Center of Matrix Biology, Vanderbilt University Medical Center. Elliott V. Newman Professor, Medicine. University of Vanderbilt, TN USA.
Jörgen Wieslander,
Ph.D.
Independent Scientific Advisor, Sweden.
Charles Swanton
M.D., Ph.D.
Professor and Chair of Personalized Cancer Medicine, University College London Cancer Institute, The Francis Crick Institute, London.
Mariano Barbacid,
Ph.D.
Professor and Leader of Experimental Oncology Group, Spanish National Cancer Research Center, Madrid, Spain.
Jorge Moscat,
Ph.D.
Professor of Cancer Metabolism and Signaling Program, Sanford-Burnham Medical Research Institute, La Jolla, CA USA.
James DeGregori,
Ph.D.
Professor, Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine Denver, CO USA.

Partnership

Silanes
University of Valencia
Center for Matrix Biology
Boehringer Ingelheim
University of Cantabria
Fundacion investigacion hospital general universitario valencia
Hospital universitario La Paz
Hospital quiron salud
Fundacion Marques de Valdecilla
Fundación investigación biomédica hospital 12 de octubre